FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029421701> ?p ?o ?g. }

• W2029421701 endingPage "456" @default.
• W2029421701 startingPage "453" @default.
• W2029421701 abstract "Despite advances in the treatment of skin psoriasis during the last years, therapy of psoriatic nails remains a challenge. Objectives The objective of this unblended, nonrandomized, open-label study was to evaluate the efficacy and safety of infliximab on nail psoriasis.Eighteen psoriatic patients with nail involvement, consecutively selected among patients scheduled to start infliximab infusions were included in the study. Thirteen of these patients had psoriatic arthritis and five had severe plaque type psoriasis. Outcome measures were assessed at baseline and at weeks 14, 22, 30 and 38 using the nail psoriasis severity index (NAPSI). Patients also filled in a Greek translation of the international onychomycosis-specific questionnaire to assess improvement in quality of life after improvement of psoriatic nail signs.All 18 patients completed the study. Significant improvement was noted in most patients after the third infusion as shown by the reduction of mean NAPSI (NAPSIm) from 55.8 at baseline to 29.8 at week 14. Evaluation after six infusions, at week 38, showed an almost complete resolution of psoriatic nail involvement (NAPSIm: 3.3). No adverse event was observed. All patients reported satisfaction with the results and significant improvement in their quality of life with reduction of the score of the international quality of life questionnaire from 66.3 at baseline to 19.1 at week 38.Alphalthough there is no control group, this data suggests that infliximab is effective for psoriatic nail disease in the context of severe skin and joint involvement." @default.
• W2029421701 created "2016-06-24" @default.
• W2029421701 creator A5002280676 @default.
• W2029421701 creator A5005721930 @default.
• W2029421701 creator A5013667203 @default.
• W2029421701 creator A5015819102 @default.
• W2029421701 creator A5024374083 @default.
• W2029421701 creator A5054976134 @default.
• W2029421701 creator A5060263598 @default.
• W2029421701 creator A5079248534 @default.
• W2029421701 date "2008-08-01" @default.
• W2029421701 modified "2023-09-23" @default.
• W2029421701 title "Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study" @default.
• W2029421701 cites W1963964611 @default.
• W2029421701 cites W1983284744 @default.
• W2029421701 cites W2024951429 @default.
• W2029421701 cites W2029499820 @default.
• W2029421701 cites W2035968875 @default.
• W2029421701 cites W2069346187 @default.
• W2029421701 cites W2082817348 @default.
• W2029421701 cites W2120422600 @default.
• W2029421701 cites W2126993279 @default.
• W2029421701 cites W2127025846 @default.
• W2029421701 cites W2134421361 @default.
• W2029421701 cites W2140626701 @default.
• W2029421701 cites W2149645081 @default.
• W2029421701 cites W2154464476 @default.
• W2029421701 cites W2172257129 @default.
• W2029421701 doi "https://doi.org/10.1111/j.1365-2133.2008.08686.x" @default.
• W2029421701 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18565184" @default.
• W2029421701 hasPublicationYear "2008" @default.
• W2029421701 type Work @default.
• W2029421701 sameAs 2029421701 @default.
• W2029421701 citedByCount "76" @default.
• W2029421701 countsByYear W20294217012012 @default.
• W2029421701 countsByYear W20294217012013 @default.
• W2029421701 countsByYear W20294217012014 @default.
• W2029421701 countsByYear W20294217012015 @default.
• W2029421701 countsByYear W20294217012016 @default.
• W2029421701 countsByYear W20294217012017 @default.
• W2029421701 countsByYear W20294217012018 @default.
• W2029421701 countsByYear W20294217012019 @default.
• W2029421701 countsByYear W20294217012020 @default.
• W2029421701 countsByYear W20294217012021 @default.
• W2029421701 countsByYear W20294217012022 @default.
• W2029421701 countsByYear W20294217012023 @default.
• W2029421701 crossrefType "journal-article" @default.
• W2029421701 hasAuthorship W2029421701A5002280676 @default.
• W2029421701 hasAuthorship W2029421701A5005721930 @default.
• W2029421701 hasAuthorship W2029421701A5013667203 @default.
• W2029421701 hasAuthorship W2029421701A5015819102 @default.
• W2029421701 hasAuthorship W2029421701A5024374083 @default.
• W2029421701 hasAuthorship W2029421701A5054976134 @default.
• W2029421701 hasAuthorship W2029421701A5060263598 @default.
• W2029421701 hasAuthorship W2029421701A5079248534 @default.
• W2029421701 hasConcept C126322002 @default.
• W2029421701 hasConcept C141071460 @default.
• W2029421701 hasConcept C151730666 @default.
• W2029421701 hasConcept C159110408 @default.
• W2029421701 hasConcept C16005928 @default.
• W2029421701 hasConcept C191897082 @default.
• W2029421701 hasConcept C192562407 @default.
• W2029421701 hasConcept C197934379 @default.
• W2029421701 hasConcept C2776173921 @default.
• W2029421701 hasConcept C2776260265 @default.
• W2029421701 hasConcept C2777138892 @default.
• W2029421701 hasConcept C2777852167 @default.
• W2029421701 hasConcept C2779134260 @default.
• W2029421701 hasConcept C2779343474 @default.
• W2029421701 hasConcept C2779951463 @default.
• W2029421701 hasConcept C2780158451 @default.
• W2029421701 hasConcept C2780564577 @default.
• W2029421701 hasConcept C71924100 @default.
• W2029421701 hasConcept C86803240 @default.
• W2029421701 hasConceptScore W2029421701C126322002 @default.
• W2029421701 hasConceptScore W2029421701C141071460 @default.
• W2029421701 hasConceptScore W2029421701C151730666 @default.
• W2029421701 hasConceptScore W2029421701C159110408 @default.
• W2029421701 hasConceptScore W2029421701C16005928 @default.
• W2029421701 hasConceptScore W2029421701C191897082 @default.
• W2029421701 hasConceptScore W2029421701C192562407 @default.
• W2029421701 hasConceptScore W2029421701C197934379 @default.
• W2029421701 hasConceptScore W2029421701C2776173921 @default.
• W2029421701 hasConceptScore W2029421701C2776260265 @default.
• W2029421701 hasConceptScore W2029421701C2777138892 @default.
• W2029421701 hasConceptScore W2029421701C2777852167 @default.
• W2029421701 hasConceptScore W2029421701C2779134260 @default.
• W2029421701 hasConceptScore W2029421701C2779343474 @default.
• W2029421701 hasConceptScore W2029421701C2779951463 @default.
• W2029421701 hasConceptScore W2029421701C2780158451 @default.
• W2029421701 hasConceptScore W2029421701C2780564577 @default.
• W2029421701 hasConceptScore W2029421701C71924100 @default.
• W2029421701 hasConceptScore W2029421701C86803240 @default.
• W2029421701 hasIssue "2" @default.
• W2029421701 hasLocation W20294217011 @default.
• W2029421701 hasLocation W20294217012 @default.
• W2029421701 hasOpenAccess W2029421701 @default.
• W2029421701 hasPrimaryLocation W20294217011 @default.

• next